United Therapeutics Co. (NASDAQ:UTHR) Stock Position Increased by Edgestream Partners L.P.

Edgestream Partners L.P. lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 61.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,117 shares of the biotechnology company’s stock after purchasing an additional 2,696 shares during the period. Edgestream Partners L.P.’s holdings in United Therapeutics were worth $2,511,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Jackson Creek Investment Advisors LLC raised its position in shares of United Therapeutics by 4.3% during the fourth quarter. Jackson Creek Investment Advisors LLC now owns 2,742 shares of the biotechnology company’s stock worth $967,000 after purchasing an additional 114 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $995,000. Callan Family Office LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $324,000. Candriam S.C.A. raised its position in shares of United Therapeutics by 11.1% during the fourth quarter. Candriam S.C.A. now owns 74,607 shares of the biotechnology company’s stock worth $26,324,000 after purchasing an additional 7,459 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of United Therapeutics during the fourth quarter worth $18,257,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on UTHR. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,464 shares of company stock worth $42,396,244 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $315.91 on Monday. The business’s 50-day moving average price is $354.52 and its two-hundred day moving average price is $360.00. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82. The company has a market capitalization of $14.19 billion, a P/E ratio of 13.87, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the previous year, the company posted $4.36 earnings per share. On average, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.